Headache News and Research

Latest Headache News and Research

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Baylor University receives two new federal grants for research on Gulf War illness

Baylor University has been awarded two new federal grants for research on Gulf War illness, the complex medical condition that affects veterans of the 1991 war. The grants, from the Office of Congressionally Directed Medical Research Programs of the U.S. Department of Defense, total nearly $1.6 million, and bring current federal funding for Baylor's Gulf War research program to over $2.3 million.

3 Nov 2012

TD-1211 may relieve opioid-induced constipation

TD-1211 – an inhibitor of the mµ-opioid receptor – alleviates chronic noncancer-related constipation in patients receiving opioid therapy, without affecting pain relief, show the results of a parallel-group study.

2 Nov 2012

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

1 Nov 2012

Children with migraine more likely to have below average school performance

Children with migraine are more likely to have below average school performance than kids who do not have headaches, according to new research published in the October 30, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

30 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

CUMC researchers develop first true mouse model of typhoid infection

Columbia University Medical Center (CUMC) researchers have created the first true mouse model of typhoid infection. The development promises to advance the study of typhoid and the creation of new vaccines against the infection, which remains a major health threat in developing countries.

26 Oct 2012

New method of testing for West Nile virus

While the United States has largely been spared the scourge of mosquito-borne diseases endemic to the developing world-including yellow fever, malaria and dengue fever-mosquito-related illnesses in the US are on the rise. One pathogen of increasing concern in the U.S. is an arbovirus known as West Nile.

24 Oct 2012

Migraine linked to depression, stress in sub-Saharan Africans

Migraine is significantly associated with stress and unipolar psychiatric symptoms in sub-Saharan African adults, researchers say.

24 Oct 2012

Review: Herbs and dietary supplements can cause potentially harmful drug interactions

A number of herbs and dietary supplements (HDS) can cause potentially harmful drug interactions, particularly among people receiving medication for problems with their central nervous or cardiovascular systems.

24 Oct 2012

NEJM report on best options for safe, effective patient treatment against fungal meningitis

As the number of fungal meningitis cases continues to rise, physicians across the country are faced with how best to provide the early treatment that can save lives.

24 Oct 2012

Bayer announces data from riociguat Phase III trial on CTEPH

Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.

24 Oct 2012

Sanofi presents overview of Phase II and III trials for quadrivalent influenza vaccine

Sanofi Pasteur, the vaccines division of Sanofi, presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV).

23 Oct 2012

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.

22 Oct 2012

Transcranial magnetic stimulation can benefit patients with depression, debilitating tinnitus

Three patients who have suffered periodic major depression throughout their adult lives told an audience attending a Loyola Grand Rounds presentation how their lives have been transformed by a new magnetic therapy.

16 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.

12 Oct 2012

Study identifies need for better definitions and diagnostic tools for sports head injuries

In recent years it has become clear that athletes who experience repeated impacts to the head may be at risk of potentially serious neurological and psychiatric problems. But a study of sports programs at three major universities, published in the October 2 Journal of Neurosurgery, finds that the way the injury commonly called concussion is usually diagnosed - largely based on athletes' subjective symptoms - varies greatly and may not be the best way to determine who is at risk for future problems.

11 Oct 2012

Migraine therapy alleviates more than just the headache

Treating the pain associated with migraine can also improve the social and psychologic problems experienced by individuals affected by the condition, findings from a systematic review suggest.

10 Oct 2012

Headache News and Research

Latest Headache News and Research

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Baylor University receives two new federal grants for research on Gulf War illness

TD-1211 may relieve opioid-induced constipation

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Children with migraine more likely to have below average school performance

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

CUMC researchers develop first true mouse model of typhoid infection

New method of testing for West Nile virus

Migraine linked to depression, stress in sub-Saharan Africans

Review: Herbs and dietary supplements can cause potentially harmful drug interactions

NEJM report on best options for safe, effective patient treatment against fungal meningitis

Bayer announces data from riociguat Phase III trial on CTEPH

Sanofi presents overview of Phase II and III trials for quadrivalent influenza vaccine

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Transcranial magnetic stimulation can benefit patients with depression, debilitating tinnitus

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Study identifies need for better definitions and diagnostic tools for sports head injuries

Migraine therapy alleviates more than just the headache

Innovation in neuroscience drug discovery - eBook eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in